<DOC>
	<DOCNO>NCT01399853</DOCNO>
	<brief_summary>Hand , foot , mouth disease ( HFMD ) common viral illness infant child cause virus belong enterovirus genus picornavirus family . Although HFMD case result serious complication , outbreak HFMD cause enterovirus 71 ( EV71 ) present high rate neurological complication , include meningoencephalitis , pulmonary complication , even cause infant death . HFMD cause EV71 become major emerge infectious disease Asia highly pathogenic potential EV71 clearly require attention world medical community . The phase I study inactivated vaccine ( vero cell ) EV71 complete last month Jiangsu Province China . The data phase I study suggest inactivated EV71 vaccine clinically acceptable safety good immunogenicity healthy Chinese child infant . In order provide evidence immunogenicity vaccine , explore probable immunize dose safety profile vaccine , phase II clinical trial plan conduct .</brief_summary>
	<brief_title>A Phase II Clinical Trial Inactivated Vaccine ( Vero Cell ) Against EV71 Chinese Children Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>For child group ( aged 1236 month ) : Healthy child age 12 36 month old establish medical history clinical examination The subject ' guardian able understand sign inform consent Had never receive vaccine EV71 Subjects comply requirement protocol Subjects temperature &lt; =37.0°C axillary setting For infant group ( age 611 month ) : Healthy infant age 6 11 month old establish medical history clinical examination The subject ' guardian able understand sign inform consent Had never receive vaccine EV71 Subjects comply requirement protocol Subjects temperature &lt; =37.0°C axillary setting For child group ( aged 1236 month ) : Subject medical history HFMD &lt; = 37 week gestation Subjects birth weight &lt; 2.5 kg Subject medical history following : allergic history , allergic ingredient vaccine Family history seizure progressive neurological disease Family history congenital hereditary immunodeficiency Severe malnutrition dysgenopathy Major congenital defect serious chronic illness , include perinatal brain damage Autoimmune disease Bleeding disorder diagnose doctor significant bruising bleed difficulty IM injection blood draw Any acute infection last 7 day Any prior administration immunodepressant corticosteroid last 6month Any prior administration blood product last 3 month Any prior administration research medicine last 1 month Any prior administration attenuate live vaccine last 28 day Any prior administration subunit inactivate vaccine last 14 day , pneumococcal vaccine Under antiTB prevention therapy Any condition opinion investigator , may interfere evaluation study objective For infant group ( age 611 month ) : Subject medical history HFMD &lt; = 37 week gestation Subjects birth weight &lt; 2.5 kg Subject medical history following : allergic history , allergic ingredient vaccine Family history seizure progressive neurological disease Family history congenital hereditary immunodeficiency Severe malnutrition dysgenopathy Major congenital defect serious chronic illness , include perinatal brain damage Autoimmune disease Bleeding disorder diagnose doctor significant bruising bleed difficulty IM injection blood draw Any acute infection last 7 day Any prior administration immunodepressant corticosteroid last 6month Any prior administration blood product last 3 month Any prior administration research medicine last 1 month Any prior administration attenuate live vaccine last 28 day Any prior administration subunit inactivate vaccine last 14 day , pneumococcal vaccine Under antiTB prevention therapy Any condition opinion investigator , may interfere evaluation study objective Exclusion Criteria second dose : Had Grade 3 Grade 4 adverse reaction within 7 day first dose Any situation meet exclusion criterion state exclusion criterion first dose Had SAE relate first dose followingup first dose Any condition opinion investigator , IRB</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>inactivate EV71 vaccine</keyword>
</DOC>